PMGC unit NorthStrive Biosciences files U.S. patent applications for EL-22, EL-32 in muscle preservation during GLP-1 weight loss
PUBT · 06/18 11:37
Share
Listen to the news
- NorthStrive Biosciences, a wholly owned unit of PMGC, filed two new U.S. patent applications tied to EL-22 and EL-32.
- Filings target preserving lean muscle mass in patients using GLP-1 and other incretin-based obesity drugs, shifting focus toward human pharmaceutical uses.
- Applications were assigned U.S. Patent Application Nos. 19/709,895 for EL-22, 19/709,950 for EL-32.
- Claims also cover combination use with muscle-support compounds, including apelin or ursolic acid, across multiple delivery formats.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending